February 22, 2018
Patients covered by Medicaid in Kentucky and Indiana could soon find themselves in a difficult position. According to new rules, recipients must complete 80 hours of “community engagement” or risk losing their health coverage.
February 13, 2018
Think an informed medical expert is making the coverage decisions at your health insurance company? You might think again.
February 7, 2018
New research from the University of Pennsylvania details prior authorization requirements for PCSK9 inhibitors. The self-injected drugs lower bad cholesterol for patients with cardiovascular disease or genetic high cholesterol. Prior authorization allows health insurers to act as a gatekeeper, deciding whether they will cover the medication when it’s prescribed by a patient’s health care provider.
October 13, 2017
What began as a safeguard against unnecessary drug spending has become a significant barrier to patient access. And as “Understanding Prior Authorization,” a new video from the Alliance for Patient Access, explains, the process may cut costs at patients’ expense.
September 13, 2017
Tens of millions of people across the United States are affected by skin conditions, but not all of them can access the doctors and medications they need. So explains a new white paper from the Derma Care Access Network, an advocacy group that encourages informed policy on access to dermatological care.
September 1, 2017
Vacation season? Perhaps. But summer hasn’t slowed the Institute for Patient Access’ steady stream of physician-led insight on policy issues that matter to patients and their health care providers.
August 24, 2017
A money-back deal for cholesterol-lowering PCSK9 inhibitors doesn’t cut costs enough, claims a new analysis from a University of Pittsburgh researcher
August 6, 2017
Respiratory illnesses are pervasive, chronic conditions that exist quietly in millions of Americans. Patients manage their breathing with varying degrees…
June 26, 2017
Health plans across the country are rejecting prescriptions for cholesterol-lowering PCSK9 inhibitors at an average rate of 43 percent. And now one patient advocacy group has a message: Enough is enough.
June 14, 2017
Clinical pathways in the age of personalized cancer care may be excluding a key component: patient perspective.
